CII-Centre of Excellence in Nanotechnology(CoE-NT), Gujarat Knowledge Application Facilitation Centre (GKAFC), Intellectual Property Facilitation Centre (IPFC) & Canada India Business Exchange(CIBX) jointly organized Industry interaction meet for Center for Commercialization of Antibodies and Biologics(CCAB), Canada on 11 February 2015, Hotel Novotel, S.G. Highway, Ahmedabad. CCAB has already developed hundreds of human antibodies that are potential therapeutic candidates for the treatment of cancer, AMD and other Infectious and Metabolic diseases.
The objective of this high profile scientific and commercial meet was to disseminate the technology offers from Canada and explore the collaboration/partnership opportunities with Indian industries, towards providing cost effective treatment options for patients in India and abroad. This initiative would further support to Prime Minister’s Make in India campaign. This was first of its kind of think tank meeting, with the participation of leading CROs, Biotechnology & pharmaceutical companies, cancer clinics and regulators, to deliberate on the possibilities.
The meeting was attended by well-renowned Personalities such as;
· Dr. H. G. Koshia, Commissioner, FDCA, Govt. of Gujarat, Gandhinagar
· Mr. Craig Brown, Chairman, CIBX, Canada
· Dr. Bhaswat Sunder Chakraborty, Sr. VP & Chair - R&D, Cadila Pharmaceuticals Ltd.
· Dr. Sanjeev Kumar, Sr. VP – Biotechnology, Zydus Research Centre, Zydus Cadila
· Dr. Sachdev Sidhu, Centre Director, CCAB, Canada
· Dr. Jason Moffat,CCAB, Canada
· Dr. D Sengupta ,Special Secretary to Govt. of India & Senior Advisor, CII
Dr Sachdev Sidhu, CEO of CCAB said, “CCAB would like to see a coupling of its world class research capabilities in the area of antibodies and biologics to develop ‘biobetter’ products with the best of India’s Biopharmaceutical and clinical research companies. This would further enable the biotech industries to accelerate development of therapeutic products and reduce the costs. Dr. Ajay Gupta discussed about various formulation related approaches which may be utilized to develop the ‘biobetters’ of these novel antibodies to reduce the dosage frequency, convert injectables to oral and thermos-stable products which will not only eliminate the need of cold-storage of the products but also self-administrable by the patients.
L-R: Harjeet Bajaj, President, Canada India Business Exchange (CIBX), Canada; Joachim Rocha, Trade Commissioner, Canadian High Commission;Dr H G Koshia, Commissioner, Food & Drug Control Authority, Govt. of Gujarat;Dr D Sengupta, Senior Advisor, Confederation of Indian Industry;Dr Sachdev Sidhu, Centre Director, Centre for Commercialization of Antibodies and Biologics, Canada; Dr Jason Moffat, Centre for Commercialization of Antibodies and Biologics (CCAB), Canada
